10-Q Detective
10-Q Detective
David Phillips
Biography
David Phillips
David Phillips has more than 25 years' experience on Wall Street, first as a financial consultant and then as an equity analyst for several investment banking firms. He sifts through SEC filings for his blog The 10Q Detective, looking for financial statement soft spots, such as depreciation policies, warranty reserves and restructuring charges. He has been widely quoted in outlets such as BusinessWeek, The International Herald Tribune, Investor's Business Daily, Kiplinger's Personal Finance, and The Wall Street Journal.
More from Commentary
-
Inside Takeda's Drug-Drought Trap
Japanese drugmaker Takeda has no shortage of things to worry about, including expiring patents, a cancer link to its leading diabetes med, and a meager pipeline.
-
Skecher's Shape-Ups Face a Flabby Future
Skechers thinks its profits will rebound once it "clears" inventory of lower-margin "Shape-up" toning shoes, but its real problems are new rivals and a flood of cheaper substitute shoes.
-
Future Demand for Cameco's Uranium Fuel Still Red-Hot, Despite Japan's Meltdown
Cameco closed lower again Thursday on fears long-term demand for uranium will slow in the aftermath of Japanese reactor problems. Even a partial meltdown at the shattered facility is unlikely to...
-
InterMune's New Lung-Disease Drug Doesn't Deserve Its Hype
Analysts think InterMune's lung-disease drug Esbriet can expect sales in excess of $1 billion annually. But it's only sold in the EU, and there's little proof the drug actually works.
-
GE's Getting Hammered, but It Won't Take the Fall for Japan's Potential Chernobyl
Shares in General Electric tumbled for a second day as fears mount of a meltdown at the Fukushima Daiichi nuclear power plant, located about 150 miles northeast of Tokyo. Given 24/7 news coverage...
-
Can Italian Oil Giant Eni SpA Prosper in a Qaddafi-Free Libya? Sure
Political unrest in Qaddafi's Libya would seem to give Italian energy giant Eni SpA a lot to worry about. But Eni's geopolitically balanced portfolio of upstream production should limit the fallout.
-
McMoran Exploration: Shallow Water, Deep Oil Drilling, Long Odds
Though its natural gas production is in decline, McMoran remains upbeat that ultra-deep prospects at shallow-water depths hold multi-trillion cubic feet of natural gas inventories. Still in their...
-
Chipotle Faces a New Risk: Commodity-Food Inflation
Rising commodity costs could do something to Chipotle that the U.S.-based operator's competition has been unable to do for years -- eat away its profits.
-
How Chipotle is Winning the Burrito Wars
Chipotle Mexican Grill doesn't do discounts or constant menu changes, but its "meal is the deal" philosophy and fast-casual fare is racking up the sales.
-
Nokia's Push into Emerging Markets: Another Bad Move?
Nokia is looking to sell more entry-level handsets in emerging markets, like India. With low-cost rivals pushing a pricing war, Nokia may be making a tactical error.
-
Nokia's Moment of Truth: Time to Hang Up on Smartphones?
Nokia Corp. is losing ground faster than expected, especially on its home turf, Europe. And the company's strategy for boosting its high-end smartphones will depress profits. Gaining at Nokia's...
-
"Americans For Truth" Fear Gay TSA Agents -- but Not Body-Scanner Lobbyists
Some anti-gay activists think TSA "pat-downs" only gratify homosexual and lesbian agents. These folks should shut up and stop distracting from a graver concern -- body-scanner influence peddlers.
-
How First Solar's Tellurium Deal Shows the Fragile Economics of Solar Panels
First Solar has signed a five-year purchase agreement with a China-based mining company for an undisclosed amount of refined tellurium (Te). The deal underscores the thin-film module maker's need...
-
Is TSA the New Gestapo? Let the Conspiracy Theories Begin
As anger from the flying public over full-body scans and pat-downs grows, conspiracists say the real enemy is a Big Brother government, not international terrorists.
-
Acorda's MS Drug Ampyra Looks Good Now, but That Probably Won't Last
Acorda Therapeutics said usage among neurologists and insurers for its new MS drug Ampyra continued to grow in the third quarter. Contrary to management's professed optimism, however, the question...
-
Solyndra Solar: Unemployment Checks Make a Better Investment Than DOE's Millions
Solyndra is closing a solar-panel factory, delaying previously announced expansion plans. Contrary to management's spin, even a cost-cutting do-over won't brighten the company's odds of survival.
-
EnCana Envisions Natural Gas Growth From Haynesville Shale -- Smell Something?
EnCana cut spending to its Haynesville Shale prospects due to oil-services shortages. A bigger concern, however, could be the marginal economics of drilling wells at prices below $4.50 for natural...
-
Mismanagement at Boeing Crashes Replacement B737 Jet
Mismanagement at Boeing won't just further delay its troubled 787 Dreamliner jet and 747-8 programs -- it could cripple replacement timelines for its flagship B737 passenger jet.
-
Dreamliner 787 Still Boeing's Nightmare Aircraft
Boeing insists the latest production glitch with the troubled 787 Dreamliner won't negatively affect its financial performance. Continued inability to hit contracted shipment dates, however, could...
-
The Sun'll Come Out Tomorrow for First Solar in the U.S.
First Solar has become a developer of utility-scale solar projects in the U.S. to ensure a captive market for its own solar modules. Construction delays, however, could lessen the profitability of...
Facebook Activity
Today on MoneyWatch
Number of Richest Soars to New High
More on Moneywatch
Hot Discussions
The best of BNET, delivered
BNET Newsletters
Get the best of BNET delivered straight to your inbox
Commentary Bloggers
Blog Archive
